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Background: There are a number of dietary components that may prove useful in the prevention and treatment
of cancer. In some cultures, fenugreek seeds are used to treat cancer. The current study focuses on the anticancer
properties and proteomic profiles of fenugreek seeds, and is prompted by the clinical profile of a case of primary
CNS T cell lymphoma that responded to fenugreek treatment and resulted in tumor regression.
Method: Various normal and cancer cell lines were exposed to fenugreek extract at differing concentrations
(100 μg/ml, 200 μg/ml and 300 μg/ml) and at different time points (0, 24, 48, 72 and 96 hrs). Protein fingerprints
of fenugreek grain/seed types, obtained from four different geographical regions, were analyzed by proteomic
expression profiles.
Results: We observed selective cytotoxic effects of fenugreek extract in vitro to a panel of cancer cell lines, including
T-cell lymphoma. Additionally, the cluster analysis of proteomics data showed that the protein profile of the particular
fenugreek used by the patient is significantly different from three other regional subtypes of fenugreek extract.
Conclusion: The in vitro effect of fenugreek as a substance with significant cytotoxicity to cancer cells points to the
potential usefulness of fenugreek in the prevention and treatment of cancer.
Keywords: Primary T-cell lymphoma, Cerebellum, T-lymphocytes cells, Trigonella foenum graecum (fenugreek), Brain
tumor, Proteomics, Hierarchical cluster analysis/protein expression, Anti-cancerBackground
There is growing use of complementary and alternative
anticancer medicines worldwide. Trigonella foenum grae-
cum (fenugreek) is traditionally applied to treat disorders
such as diabetes [1], high cholesterol [2], wound inflam-
mation [3], and gastrointestinal ailments [4]. Fenugreek
is also reported to have anticancer properties due to its
beneficial active chemical constituents. It’s mechanism
of action is similar to several anticancer drugs, and is
based on an ability to induce apoptosis [5].
The current in vitro studies were prompted by the
clinical profile of a previously reported case of primary
CNS T cell lymphoma [6]. Brain MRI with contrast was
performed and revealed numerous cerebellar-enhancing
lesions with secondary hydrocephalus (Figure 1). Brain* Correspondence: alsemari@kfshrc.edu.sa
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reproduction in any medium, provided the orbiopsy of cerebral lesions showed a lympho-proliferative
lesion. Histochemistry indicated T-cell infiltration of
the cerebellum. Immunochemistry revealed immature
T-lymphocytes (CD3, CD7, CD5) and mature lympho-
cytes (CD4, CD2).
The patient initially went into clinical remission for
37 months after chemotherapy and radiotherapy. After
three years of remission, the patient’s disease relapsed
with intermittent weakness in her left arm and deviation
of her mouth to the left. MRI of the brain with contrast
showed a new enhanced lesion in the right frontoparietal
region (Figure 2). The lesion was biopsied and the histo-
pathology analysis confirmed the recurrence of her lymph-
oma. The patient was put on terminal care because the
family refused treatment and took the child home [6].
The family decided to treat their child with concentrated
extract of fenugreek, boiled in regular water. The approxi-
mate daily treatment amount was 8 g of fenugreek seeds,
over the course of 6 months. Repeat brain MRI threel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Brain MRI with contrast shows cerebellar enhancing lesions with secondary hydrocephalus.
Figure 2 Brain MRI shows new enhanced lesion in the right frontoparietal lesion.
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new right intra cerebral lesion frontoparietal (Additional
file 1: Figure S1). The subsequent brain MRI after six
months showed complete resolution of the relapsed lesion
(Figure 3). The patient continued in remission for 11 years;
however, she had a devastating relapse in early 2012 and is
currently emaciated and bed ridden. A repeat brain MRI
in June 2012 showed new enhanced lesions and diffuse
high signals on the right hemisphere (Additional file 2:
Figure S2, ABCD).
In this report we demonstrate the selective cytotoxic
effects of fenugreek extract in vitro on a panel of cancer
cell lines, and a proteomics analysis of fenugreek.Methods
Patient material
The patient consented for the publication of the clinical
report. The study was approved by the Office of Research
Affairs (ORA under the umbrella of Research Advisory
Council (RAC) of King Faisal Specialist Hospital and
Research Center (KFSHRC), with approval umber RAC#.
2120 006.
In order to avoid sample source variability all samples
analyzed were purchased from the same local grocery
store used by the patient.
Cell culture and fenugreek extraction
A variety of normal and cancer cell lines including; T-cell
lymphoma (TCP), B-cell lymphomas, Thyroid PapillaryFigure 3 Brain MRI with contrast shows complete resolution of relapsecarcinoma (FRO) and human breast cancer (MCF7) were
obtained from American Type Culture Collection (ATCC).
Cells were cultivated at 37°C and 5% CO2 in Dulbecco’s
MEM (DMEM) containing 5% fetal bovine serum, 3 mM
glutamine (Gibco, NJ, USA) and antibiotics.
Fenugreek seeds were extracted in water, filtered, and
concentrated with minor modification [7]. The extract
was reconstituted to a working stock concentration of
50 mg/ml [8]. Cells were exposed to fenugreek extract
at different concentrations (100 ug/ml, 200 ug/ml and
300 ug/ml) [9] and at different time points (0, 24, 48,
72 and 96 hrs).
Cell viability assay
Cells were seeded onto a 96-well plate at a density of
5000 cells/well. In order to achieve meaningful quantitative
analysis, duplicate or triplicates samples were subsequently
incubated at 37°C for 72 hrs. in a titrated medium con-
taining different concentrations of fenugreek extract. The
number of viable cells was estimated using the protocol of
3-(4,5-dimethylthazol-2yl)-2,5-diphenyletrazlium bromide
(MTT)-assay (Promega, Madison, WI, USA).
Apoptosis analysis by annexin V staining
Approximately 5 × 105 cells were seeded and cultured in
60 mm plates to 50-70% confluence. Triplicate samples
were subsequently incubated at 37°C for 72 hours in a
titrated medium containing different concentrations
of fenugreek extract. The applied fenugreek extract
was re-constituted in sterile water to yield the desiredd lymphoma.
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48, 72 and 96 hours, centrifuged and re-suspended in
1 ml of PBS. Thereafter, cells were stained with Propidium
Iodide (PI) and Alexa Fluor 488 Annexin V, using Vybrant
Apoptosis Assay kit #2 (molecular probes) according to
the manufacturer’s protocol. Stained cells were analyzed
by flow cytometry. Viable cell percentages were deter-
mined by the FACS Calibur apparatus and the Cell Quest
Pro software from Becton Dickinson (BD Biosciences).
Proteomics analysis of anticancer effects of fenugreek
proteins on brain tumor
Protein patterns of different types of fenugreek grains/
seeds were obtained from four different regions (labeled
A-D). All four fenugreek types were analyzed by two-
dimensional polyacrylamide gel electrophoresis (2-DE)
for global differential protein expression profiles. The
aim was to identify significantly differentially expressed
proteins, and to identify proteins that are cancer related
amongst the four types. The potential clinical applica-
tions of these proteins will be further evaluated.
Electrophoresis, scanning and image analysis
Seeds/grains from four different fenugreek types were
ground and protein extracted. The samples were diluted to
a total volume of 350 μl, in a solution containing 8 M urea,
2 M thio urea, 0.2% Pharmalyte, 0.3% DTT, 2 M CHAPS
and a trace of bromphenol blue. A total amount of 75 μg of
protein was loaded on each strip via rehydration using
linear pH 4–7 Ready IPG, strips (Bio-Rad, Hercules, CA,
USA). First-dimension isoelectric focusing was carried out
for a total of 45,500 Vh in a PROTEAN IEF cell (Bio-Rad).
The IPG-strips were then loaded and run on a 12.5%
SDS-PAGE gel overnight at 100 V (constant) until the
bromophenol blue dye front had reached the bottom
of the gel. The gels were stained with silver nitrate and
scanned using a calibrated densitometer, GS 800 and
data was analyzed using PDQUEST software (Bio-Rad).
Between 3–4 gels were run from each sample to allow
for significant statistical analysis and ensure sample
reproducibility.
Data preprocessing/data analysis
A difference of ≥ 2-fold change was used as a threshold for
marked quantitative difference between pairs of samples.
Significantly differentially expressed protein spots were
first selected using two different statistical methods
(Student’s t test and Partial Least Square analysis), features
available in PDQuest 2-DE image analysis software. The
data from the match set was exported from PDQUEST
in the form of a data table, with rows representing gels
and columns representing spots. Datasets were normal-
ized prior to analysis [10,11]. The resulting data weresubjected to hierarchical clustering analysis using the J
Express software (java.sun.com).
Results
Cytotoxic effect of fenugreek on normal and cancer cells
We found that fenugreek extract has a very selective cyto-
toxicity against cancer cell lines such as T-cell lymphoma
(TCP), B-cell lymphomas, Thyroid Papillary carcinoma
(FRO) and breast cancer (MCF7). On the other hand,
there was no significant cell cytotoxicity amongst normal
cells, including human lymphocytes and meningioma,
when treated with fenugreek. This clearly indicates that
fenugreek has selective cytotoxic effects against cancer
cells (Additional file 3: Figure S3).
Fenugreek selectively induces apoptosis in cancer and
normal cells
Apoptosis and necrosis of normal and cancer cells was
measured using Annexin V apoptosis assay kit Viable cells,
necrotic cells, and apoptotic cells were gated utilizing PI
and Annexin V staining. We observed significant fractions
of apoptotic cells when normal T-cell lymphocytes and
cancer cells (T-cell lymphoma-TCP, and human Thyroid
papillary carcinoma-FRO) were treated with 300 μg/ml
of fenugreek for 24 and 72 hours respectively. There
was a high degree of both early apoptosis (Additional
file 4: Figure S4 - cells in lower right corner) and late
apoptosis (cells in upper right panel). The fractions of cells
undergoing apoptosis due to fenugreek are significantly
higher in all the studied cancer cells compared with nor-
mal cells (Figure 4, Additional files 4 and 5: Figure S4, S5
and Additional file 6: Table S1). All the data was generated
using a FACSCaliber flow cytometer.
Comparison of protein expression patterns between the
four regional fenugreek samples
An average total number of 790 spots were resolved and
minimum of 88.5% of the spots were matched between
all the gels. Samples were run in triplicate gels to allow for
analysis of statistical significance. Marked quantitative
and qualitative similarities were observed in the protein
expression profiles of all four fenugreek types. In addition,
differential protein expression data revealed marked
changes only in the expression profiles between sample
A (The extract taken by the patient) and the other fenu-
greek types B, C & D. The similarity in protein expression
between pairs of fenugreek samples was observed using
the correlation analyses between two types of samples.
When pairs of B/C/D samples were compared an average
correlation coefficient of 0.86 was observed. However, we
observed a significant degree of heterogeneity in the protein
expression between pairs of A/B, A/C and A/D, with an
average correlation of only 0.38 (Additional file 6: Table S2).
Figure 4 Flow cytometric graphs of T-cell lymphoma without fenugreek treatment (A) and when treated with 300 μg/ml of Fenugreek,
for 24, and 72 hours, B and C respectively. The very low number of cells migrated to the right- upper panel are the dead cells by apoptosis
induction (late apoptosis) the right lower is the early apoptosis indicating that the apoptotic cell cytotoxicity of fenugreek is very low in normal
T-cell lymphocytes cell line. Apoptosis and necrosis was measured using Annexin V apoptosis assay kit. (Molecular Probe). The graphical distribution of
viable cells, necrotic and population of apoptotic cells was gated according to their staining signals to PI and Annexin V. The data was generated using
a FACS caliber flow cytometry.
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ples are shown in Figure 5.
Hierarchical cluster analysis of differentially expressed
proteins between the four regional fenugreek samples
Matched spots on the gels were compared to investigate
differences in protein expression patterns. Protein expres-
sion data of a distinct set of 105 differentially expressed
protein spots were examined. These differences were
statistically significant using Partial Least Square analysis
(PLS, P < 0.05) between sample A and the other three
fenugreek types (B/C/D) combined. The resulting dataset
from these 105 differentially expressed proteins were
then subjected to hierarchical cluster analysis. A distinctive
‘heat map’ separating fenugreek A from the remaining
three samples was observed (Figure 6A). Because of the
limited sample size, we used another statistical method,
Student’s- t test, to select variables that may discriminate
between the three sample groups. This analysis resulted
in 70 protein spots that differ significantly between the
four sample groups. The resulting dataset from these 70
differentially expressed protein spots were then used for
possible classification of the samples into their respect-
ive groups, using hierarchical cluster analysis. All the A
samples were distinct from the other samples, similar to
the pattern observed in Figure 6A (data not shown). To
reduce the proteins within the dataset to a more practical
number, a total of 8 protein spots, that fall in the inter-
section of the above two data sets, were selected. All
fenugreek A samples were correctly classified away from
the other three fenugreek sample types (B/C/D) using the
8 protein spot dataset (Figure 6B). The fact that the rest
of the fenugreek types share more similarities in their
expression patterns might explain why there is no distinct
clustering of these three sample types. The localization
on the 2-DE gel, as well as the differential expressionsof some of these protein spots (shown as histograms),
is indicated in Additional file 7: Figure S6.
Some of the differentially expressed protein spots, that
are absent or down-regulated in the fenugreek A samples
compared with the remaining three fenugreek types, are
shown in Additional file 7: Figure S6. On the other hand,
the up-regulated protein spots in the fenugreek A samples,
as compared to the other fenugreek samples, are shown as
gel segments in Additional file 8: Figure S7AB.
The clustering data, taken together with the correlation
analyses of protein expression patterns, showed clearly that
three fenugreek types (B/C/D) were very similar (average
correlation coefficient = 0.86) compared with fenugreek
A (r = 0.38). This indicates that even though there might
be different fenugreek species, the medicinal properties
they possess may be due to specific proteins that span
the regional/species differences.
Discussion
Despite the rarity of T-cell lymphomas, primary CNS
lymphoma has a, distinctive clinical presentation [12-17],
and has a poor prognosis [18]. The standard first-line
treatment, of radiation therapy and chemotherapy, can
achieve a complete response in only 20%–50% of patients.
And the reported median survival for T-cell CNS lymph-
omas is between 13.5 and 22 months [17,19].
Our case study, to our knowledge, is the first of its
kind to show the anticancer properties of fenugreek in
a patient with established relapsed primary CNS lymph-
oma. The daily use of aqueous extract of fenugreek
resulted in 11 years remission of relapsed primary CNS
T- cell lymphoma. Also our experimental research, in vitro,
showed that fenugreek is also selectively cytotoxic to
cancer, and not to normal cells. Normal lymphocytes
showed no apoptosis while T-Cell lymphoma and breast
cancer cells were highly apoptotic following fenugreek
treatment.
Figure 5 Representative 2-DE gels derived from all the 4 different regional Fenugreek samples. (A): Fenugreek taken by the patient.
(B, C and D): Fenugreeks form other regions.
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cancer response to aqueous fenugreek. The distinctive,
long duration, remission of a patient with relapsed primary
T-cell lymphoma after daily use of aqueous extract of a
particular Trigonella foenum graecum, however remarkable,
only represents a single case. A more rigorous scientific
evaluation, such as a clinical trial, is obviously warranted
before the anti cancer properties of fenugreek can be
confirmed
Nonetheless, alternative medicine use is widespread
amongst cancer patients. In many surveys, herbal medi-
cines are amongst the most commonly used treatments.
Herbal remedies are believed by the general public to
be safe, cause less side-effects and be less likely to cause
dependency [20]. However most of these perceptions have
not been studied in prospective research.
Extracts of fenugreek seeds, and some of their constitu-
ents, have been shown to have anti carcinogenic potency
[21-23]. Anti cancer properties of fenugreek, or its constitu-
ents, involve multiple functional and molecular targets.Fenugreek induced apoptosis has been reported in a wide
variety of tumor cell lines including human; colon [24],
osteosarcoma [25], leukemia [26], breast [27], and liver [28].
The preventive efficacy of dietary fenugreek seed, and
its major constituent, diosgenin, on azoxymethane-induced
rat colon carcinogenesis during initiation and promotion
stages has been evaluated [24]. These in vitro experiments
indicated that diosgenin inhibits cell growth and induces
apoptosis in the HT-29 human colon cancer cell line in a
dose-dependent manner. Furthermore, diosgenin induced
apoptosis in HT-29 cells at least in part by inhibition of bcl-
2 and by induction of caspase-3 protein expression. This
study suggests the fenugreek constituent, diosgenin, has
potential as a novel preventive agent for colon cancer [24].
Another study suggested significant chemo preventive
effect of fenugreek seeds against breast cancer [29].
Fenugreek seed extract was demonstrated to signifi-
cantly inhibit MDA 231-induced mammary hyperplasia
and decreased its incidence. The authors further suggest
that apoptosis might mediate fenugreek’s protective anti-
Figure 6 Hierarchical Cluster analysis of fenugreek samples from region A away from the other three different regional fenugreek types using
expression dataset from (A) 105 and (B) 8 protein spots that differed significantly using PLS and students-t test analyses respectively.
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by fenugreek extract is suggested by its ability to increase
the expression of pro-apoptotic genes, and thus this spice
holds promise for consideration in complementary ther-
apy for breast cancer [5].
In a recent study, fenugreek was demonstrated to be
cytotoxic to a panel of cancer but not normal cells [23].
Treatment with 10–15 μg/mL of fenugreek for 72 h was
found to be growth inhibitory to breast, pancreatic and
prostate cancer cell lines. When tested at higher doses
(15–20 μg/mL), fenugreek continued to be growth inhibi-
tory to prostate cancer cell lines but not to either primary
prostate or normal prostate cell lines. At least part of the
growth inhibition was reported to be due to induction of
cell death, as seen by incorporation of Ethidium Bromide
III into cancer cells exposed to fenugreek [23].
Protodioscin (PD) has been purified from fenugreek and
identified by Mass, and 1H- and 13C NMR. The effects
of PD on cell viability in human leukemia (HL-60) and
human stomach cancer (KATO III) cells have been in-
vestigated. PD displayed strong growth inhibitory effect
against HL-60 cells, but weak growth inhibitory effect
on KATO III cells. Morphological changes (apoptotic
bodies) have been observed in HL-60 cells treated with
PD, but not in KATO III cells treated with PD. These
findings suggest that growth inhibition of HL-60 cells
by PD results from the induction of apoptosis [21].Al-daghri [30] reported that incubation of Jurkat T
lymphocytes cells with fenugreek extract at concentrations
ranging from 30 to 1500 μg/mL, for up to 3 days resulted
in cell death in a dose- and time-dependent manner.
Jurkat cell death was preceded by the appearance of
multiple large vacuoles, which coincided with transcrip-
tional up-regulation of the autophagy marker LC3 [30].
Distinct morphological changes including the appearance
of large vacuoles, membrane disintegration and increased
expression of autophagy protein LC3 transcripts indicated
that fenugreek extract induced autophagy and autophagy-
associated death of Jurkat cells [30].
Autophagy is a physiological response to stress and
has been suggested to enable cells to adapt and survive
and, hence, is considered a pro-survival mechanism [31].
Apoptosis is the best-described form of programmed cell
death, but autophagy reportedly contributes to cell death
as well. It has also been defined as an extremely conserved
process of programmed cell death and its activation causes
cell death [32]. Defective regulation of autophagy in can-
cers suggests that autophagy is a true tumor suppressor
pathway [30].
It has been suggested that environmental and geograph-
ical differences may significantly influence the biologically
active components of fenugreek extracts [24]. In our study,
four different types of fenugreek were analyzed by pro-
teomics fingerprinting. A set of eight protein spots from
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were significantly different from those harvested from three
different geographical locations (B, C & D). Our proteomics
data, based on these eight protein spots, allowed accurate
discrimination between regional fenugreek A and three
other fenugreek samples B, C and D.
These proteins are of significant interest, and thus war-
rant further characterization to more fully explore their
potential therapeutic use. We recognize the limited sample
size of this preliminary study, however our results are of
significant interest as they highlight the potential useful-
ness of a particular type of fenugreek as an anti-cancer
drug. However, these exciting results obviously warrant
additional study, including further drug characterization
and development.
Conclusions
In summary, to our knowledge, this is the first human
case in which established malignant CNS cancer showed
regression, then disappearing of the cancer lesion with daily
use of fenugreek extract. Fenugreek may serve as a poten-
tial therapeutic in the treatment of lymphoid malignancy
and other cancers. GC-MS analysis of fenugreek extract
indicated the presence of several compounds with anti-
cancer properties, including gingerol, cedrene, zingerone,
vanillin and eugenol [30]. However whole crude extract
has been shown to provide more selective potential than
these individual compounds used in isolation [23]. Also it
must be considered that the biologically active agents in
fenugreek may vary based on geographical environments.Additional files
Additional file 1: Figure S1. Brain MRI with contrast shows significant
improvement of the new right frontoparietal intra cerebral lesion.
Additional file 2: Figure S2. A, B: Brain MRI with contrast shows
enhanced lesion. C, D: Brain MRI Flair sequence with new diffuse high
signals over the right hemisphere.
Additional file 3: Figure S3. Fenugreek exerted cytotoxicity effect on
normal and cancer cells. The Cell-viability was measured by positive staining
using propidium iodide. (LCL, Human Normal Lymphocytes, TCP are T-cell
lymphoma, and FRO are the human Thyroid papillary carcinoma).
Additional file 4: Figure S4. Flow cytometric graphs of T-cell lymphocytes
(Normal cells) when treated with 300 μg/ml of Fenugreek, for 24, and 72 hours
respectively. The very low number of cells migrated to the right- upper
quadrant are the dead cells by apoptosis induction (late apoptosis) the right
lower is the early apoptosis indicating that the apoptotic cell cytotoxicity of
fenugreek is very low in normal T-cell lymphocytes cell line. Apoptosis and
necrosis was measured using Annexin V apoptosis assay kit. (Molecular
Probe). The graphical distribution of viable cells, necrotic and population of
apoptotic cells was gated according to their staining signals to PI and
Annexin V. The data was generated using a FACS caliber flow cytometry.
Additional file 5: Figure S5. Apoptosis and cell viability in: Normal
lymphocytes (LCL) (Blue)) showed no apoptosis, no cell killing, while the
T-Cell lymphoma (Red column) and the Anaplastic Thyroid (FRO) (Green
column); showed similar high cell cytotoxicity by apoptosis when incubated
with fenugreek.Additional file 6: Table S1. Fenugreek cytotoxicity and Apoptotic
effects on different cancer and normal cells. Table S2. Correlation analysis of
pairs of 2-DE gels of fenugreek samples from four different regions A, B, C
and D. Note the poor correlation between pairs of fenugreek from region
A vs. B/C/D, compared with good correlation among pairs of D/C,B/D, C/B.
Additional file 7: Figure S6. Global protein analysis showing
expression levels of 8 protein spots that differs significantly between the
fenugreek samples from region A and the rest three different regional
fenugreek sample types using Student’s t- test.
Additional file 8: Figure S7. AB: Gel segments of showing protein
spots that are only present (A, upper panel) or absent (B, lower panel) in
fenugreek samples from region A compared with the rest three other
regional fenugreek samples B, C and D.
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